1813 tracked 13F filers disclose a position in CVS as of the latest SEC 13F filings, a combined $70.5B in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $9.0B | 125.9M | ▲+4.1% Added · +4.9M sh | Q1 2026 | |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $5.9B | 82.7M | →First observed position No prior filed position | Q1 2026 | |
| 3 | STATE STREET CORP | $6.2B | 60.3M | ▲+1.6% Added · +961K sh | Q2 2026 | |
| 4 | DODGE & COX | $3.7B | 51.8M | ▼−17% Reduced · −10.7M sh | Q1 2026 | |
| 5 | FMR LLC | $2.2B | 31.2M | ▼−24% Reduced · −9.8M sh | Q1 2026 | |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | $3.1B | 29.9M | ▲+1.5% Added · +441K sh | Q2 2026 | |
| 7 | JPMORGAN CHASE & CO | $2.1B | 29.5M | ▼−5.4% Reduced · −1.7M sh | Q1 2026 | |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | $1.9B | 26.0M | →First observed position No prior filed position | Q1 2026 | |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | $1.7B | 23.8M | ▲+45% Added · +7.3M sh | Q1 2026 | |
| 10 | NORGES BANK | $1.7B | 21.0M | ▲+6.6% Added · +1.3M sh | Q4 2025 | |
| 11 | MORGAN STANLEY | $1.3B | 17.8M | ▼−13% Reduced · −2.5M sh | Q1 2026 | |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $983.2M | 13.7M | ▼−1.3% Reduced · −182K sh | Q1 2026 | |
| 13 | GOLDMAN SACHS GROUP INC | $907.8M | 12.6M | ▲+54% Added · +4.4M sh | Q1 2026 | |
| 14 | PZENA INVESTMENT MANAGEMENT LLC | $1.2B | 11.8M | ▼−15% Reduced · −2.0M sh | Q2 2026 | |
| 15 | NORTHERN TRUST CORP | $836.1M | 11.6M | ▼−1.6% Reduced · −190K sh | Q1 2026 | |
| 16 | Legal & General Group Plc | $683.4M | 9.5M | ▲+2.2% Added · +207K sh | Q1 2026 | |
| 17 | BANK OF AMERICA CORP /DE/ | $671.7M | 9.4M | ▼−0.7% Reduced · −68K sh | Q1 2026 | |
| 18 | Bank of New York Mellon Corp | $648.5M | 9.0M | ▼−0.9% Reduced · −80K sh | Q1 2026 | |
| 19 | ROYAL BANK OF CANADA | $645.3M | 9.0M | ▼−3.0% Reduced · −277K sh | Q1 2026 | |
| 20 | AMERIPRISE FINANCIAL INC | $643.1M | 9.0M | ▲+11% Added · +903K sh | Q1 2026 | |
| 21 | Clearbridge Investments, LLC | $630.2M | 8.8M | ▼−0.2% Reduced · −17K sh | Q1 2026 | |
| 22 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME | $596.0M | 8.3M | ▼−0.2% Reduced · −14K sh | Q1 2026 | |
| 23 | WELLS FARGO & COMPANY/MN | $582.5M | 8.1M | ▲+18% Added · +1.2M sh | Q1 2026 | |
| 24 | Amundi | $529.4M | 7.4M | ▲+26% Added · +1.5M sh | Q1 2026 | |
| 25 | DIMENSIONAL FUND ADVISORS LP | $516.8M | 7.2M | ▲+3.0% Added · +207K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 0 funds opened a new position in CVS and 25 added to an existing one, while 22 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| MICROSOFT CORPMSFT | 1171 funds | $369.0B |
| APPLE INCAAPL | 1164 funds | $413.8B |
| AMAZON.COM INCAMZN | 1153 funds | $281.2B |
| NVIDIA CORPNVDA | 1150 funds | $523.1B |
| ALPHABET INC-CL AGOOGL | 1148 funds | $252.0B |
| JPMORGAN CHASE & COJPM | 1125 funds | $98.4B |
| META PLATFORMS INC-CLASS AMETA | 1117 funds | $157.1B |
| JOHNSON & JOHNSONJNJ | 1099 funds | $68.6B |
| ALPHABET INC-CL CGOOG | 1097 funds | $173.2B |
| ELI LILLY & COLLY | 1095 funds | $118.4B |
| BROADCOM INCAVGO | 1083 funds | $207.2B |
| ABBVIE INCABBV | 1082 funds | $48.7B |
Ranked by how many of CVS's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| May 21, 2026 | ROBBINS LARRY | Director | Sell (S) | 370K | $34.6M |
| May 20, 2026 | ROBBINS LARRY | Director | Sell (S) | 798K | $74.6M |
| May 20, 2026 | ROBBINS LARRY | Director | Sell (S) | 153K | $14.5M |
| May 20, 2026 | ROBBINS LARRY | Director | Sell (S) | 67K | $6.4M |
| May 20, 2026 | ROBBINS LARRY | Director | Sell (S) | 800 | $77K |
| May 19, 2026 | ROBBINS LARRY | Director | Sell (S) | 2.0M | $187.3M |
| May 19, 2026 | ROBBINS LARRY | Director | Sell (S) | 151 | $14K |
| May 8, 2026 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Sell (S) | 70K | $6.2M |
| Aug 20, 2025 | Finucane Anne A. | Director | Sell (S) | 8K | $533K |
| Jun 5, 2025 | SANSONE GUY P | Director | Buy (P) | 2K | $100K |
| May 6, 2025 | ROBBINS LARRY | Director | Sell (S) | 150K | $10.0M |
| May 5, 2025 | ROBBINS LARRY | Director | Sell (S) | 97K | $6.6M |
Connected entities for CVS
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/CVS/capital-change-brief"
Use Arkolith's capital_change_brief for CVS. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for CVS. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.